Acquired Company
AlloVir completed its merger with Kalaris Therapeutics, Inc. on March 18, 2025, and the combined company began trading on Nasdaq under the ticker KLRS.
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. Show more
Location: 628 Middlefield Road, Palo Alto, CA, 94301, United States | Website: https://kalaristx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
166.1M
52 Wk Range
$2.14 - $12.90
Previous Close
$8.88
Open
$8.75
Volume
3,272
Day Range
$8.75 - $9.00
Enterprise Value
96.61M
Cash
77.0M
Avg Qtr Burn
-9.791M
Insider Ownership
12.59%
Institutional Own.
79.41%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
TH103 Details Neovascular Age-Related Macular Degeneration (nAMD) | Phase 1/2 Data readout |